A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Abemaciclib (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CYCLONE 2
- Sponsors Eli Lilly and Company
- 21 Mar 2024 Planned End Date changed from 15 Jun 2026 to 1 Jun 2026.
- 06 Dec 2023 Planned primary completion date changed from 14 Nov 2023 to 2 Jan 2024.
- 20 Oct 2023 Planned primary completion date changed from 3 Nov 2023 to 14 Nov 2023.